Mitsubishi UFJ Trust & Banking Corp lessened its holdings in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 850,112 shares of the medical research company’s stock after selling 16,894 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.22% of Thermo Fisher Scientific worth $148,319,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. BB&T Securities LLC grew its stake in Thermo Fisher Scientific by 4.4% during the 1st quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in Thermo Fisher Scientific by 0.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock valued at $101,317,000 after buying an additional 5,213 shares in the last quarter. Mitchell Capital Management Co. increased its position in Thermo Fisher Scientific by 40.3% during the 2nd quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock valued at $7,841,000 after buying an additional 12,910 shares in the last quarter. Toronto Dominion Bank increased its position in Thermo Fisher Scientific by 53.5% during the 1st quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock valued at $16,450,000 after buying an additional 37,307 shares in the last quarter. Finally, IBM Retirement Fund increased its position in Thermo Fisher Scientific by 117.7% during the 2nd quarter. IBM Retirement Fund now owns 9,537 shares of the medical research company’s stock valued at $1,860,000 after buying an additional 5,157 shares in the last quarter. Hedge funds and other institutional investors own 83.36% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Mitsubishi UFJ Trust & Banking Corp Has $148.32 Million Stake in Thermo Fisher Scientific Inc (TMO)” was first reported by Marea Informative and is the property of of Marea Informative. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at http://www.mareainformativa.com/mitsubishi-ufj-trust-banking-corp-has-148-32-million-stake-in-thermo-fisher-scientific-inc-tmo/115162/.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 190.33 on Wednesday. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $194.30. The stock has a 50 day moving average of $185.02 and a 200-day moving average of $173.34. The firm has a market cap of $74.25 billion, a price-to-earnings ratio of 33.16 and a beta of 1.05.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.03 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.32%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.45%.

In other news, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the transaction, the director now directly owns 38,757 shares in the company, valued at $6,702,635.58. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Peter E. Hornstra sold 3,894 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now owns 19,751 shares in the company, valued at $3,657,490.18. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 52,738 shares of company stock worth $9,302,112. 0.49% of the stock is currently owned by corporate insiders.

TMO has been the subject of several recent analyst reports. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price target for the company in a report on Thursday, September 7th. Morgan Stanley restated an “overweight” rating and set a $220.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. Cowen and Company restated a “buy” rating and set a $200.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, September 1st. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $202.21.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.